Paula Green Sells 892 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Key Points

• Paula Green, Senior Vice President at Twist Bioscience, sold 892 shares of stock for approximately $22,978, reducing her position by 0.71% and leaving her with about 124,837 shares valued at around $3.22 million.
• Twist Bioscience’s stock opened at $25.09 with a 12-month trading range between $24.28 and $55.33, and the company has a market cap of $1.51 billion.
• Analysts have given Twist Bioscience a "Moderate Buy" rating on average, with a target price of $49.40, reflecting positive market sentiment towards the company's future prospects.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) SVP Paula Green sold 892 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $25.76, for a total value of $22,977.92. Following the completion of the transaction, the senior vice president owned 124,837 shares in the company, valued at approximately $3,215,801.12. This trade represents a 0.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Paula Green also recently made the following trade(s):

• On Friday, June 20th, Paula Green sold 292 shares of Twist Bioscience stock. The stock was sold at an average price of $35.76, for a total value of $10,441.92.

Twist Bioscience Trading Down 0.0%

NASDAQ:TWST traded down $0.00 on Wednesday, reaching $25.09. The company's stock had a trading volume of 544,821 shares, compared to its average volume of 1,198,913. Twist Bioscience Corporation has a 12-month low of $24.28 and a 12-month high of $55.33. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -17.37 and a beta of 2.31. The stock has a 50 day moving average price of $31.29 and a 200 day moving average price of $34.55.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%.The firm had revenue of $96.06 million for the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of TWST. Versant Capital Management Inc raised its stake in Twist Bioscience by 547.2% during the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after buying an additional 580 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Twist Bioscience by 68.1% during the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after purchasing an additional 303 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of Twist Bioscience in the fourth quarter valued at $58,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Twist Bioscience by 15.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock valued at $85,000 after purchasing an additional 302 shares in the last quarter. Finally, Geneos Wealth Management Inc. purchased a new stake in shares of Twist Bioscience during the second quarter worth $97,000.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Cowen reissued a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Evercore ISI set a $46.00 target price on Twist Bioscience in a research note on Monday, August 4th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $49.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.